IL-17 targeted therapies for psoriasis

Expert Opinion on Investigational Drugs

Volumn 22, Issue 8, 2013, Pages 993-1005

  Chiricozzi, Andrea ^a,b   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Anti IL 17 agents; Brodalumab; IL 17; Ixekizumab; Psoriasis; Secukinumab

Indexed keywords

ADALIMUMAB; BRODALUMAB; INTERLEUKIN 17; INTERLEUKIN 17B; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 25; INTERLEUKIN 27; IXEKIZUMAB; PROTEIN; SECUKINUMAB; UNCLASSIFIED DRUG; USTEKINUMAB;

ARTHRITIS; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENVIRONMENTAL FACTOR; ERYTHROCYTE SEDIMENTATION RATE; FUTUROLOGY; GENE EXPRESSION; HEADACHE; HEREDITY; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; MYELOID DENDRITIC CELL; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHINOPHARYNGITIS; TH2 CELL; THERAPY EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS GENE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL FACTORS; HUMANS; INTERLEUKIN-17; PSORIASIS; TRANSCRIPTOME;

EID: 84880248483     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.806483     Document Type: Review

References (99)

1. Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology 2006;212(4):327-37
2. Boehncke WH, Sterry W. Psoriasis - a systemic inflammatory disorder: Clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges 2009;7(11):946-52
3. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130(7):1785-96
4. Gladman DD. Psoriatic arthritis. Dermatol Ther 2004;17(5):350-63
5. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141(12):1527-34
6. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321-8
7. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157(6):1249-51
8. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32(6):982-6
9. Ena P, Madeddu P, Glorioso N, et al. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985;40(2):199-205
10. Mcdonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978;99(5):469-75
11. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41
12. Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: A cohort study. Br J Dermatol 2012;166(4):811-18
13. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: A case-control study. Acta Derm Venereol 2010;90(1):23-6
14. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006;212(2):123-7
15. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41(3 Pt 1):401-570
16. Burden AD. Health economics and the modern management of psoriasis. Br J Dermatol 2010;163(4):670-1
17. Vardy D, Besser A, Amir M, et al. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002;147(4):736-42
18. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23(Suppl 2):1-70
19. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009;84:14-24
20. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
21. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
22. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98
23. Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm 2006;74:255-82
24. Rouvier E, Luciani MF, Mattei MG, et al. CTLA 8, cloned from an activated T cell, bearing AU rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993;150:5445-56
25. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155(12):5483-6
26. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32
27. Ortega C, Fernandez AS, Carrillo JM, et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86:435-43
28. Laggner U, Di Meglio P, Perera G, et al. Identification of a novel pro-inflammatory human skin-homing Vc9Vd2 T cell subset with a potential role in psoriasis. J Immunol 2011;187:2783-93
29. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500
30. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011;23(5):613-19
31. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67
32. Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cysteine knot fold: Structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001;20:5332-41
33. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-74
34. Hurst SD, Muchamuel T, Gorman DM, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: In vivo function of the novel cytokine IL-25. J Immunol 2002;169:443-53
35. Kim MR, Manoukian R, Yeh R, et al. Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood 2002;100:2330-40
36. Kelly MN, Kolls JK, Happel K, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005;73:617-21
37. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194(4):519-27
38. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004;190(3):624-31
39. Happel KI, Zheng M, Young E, et al. Cutting edge: Roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003;170(9):4432-6
40. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:1310-16
41. Chao CC, Chen SJ, Adamopoulos IE, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011;44(3):243-52
42. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006;177(1):566-73
43. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421(6924):744-8
44. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201(2):233-40
45. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445(7130):866-73
46. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012;130(1):145-54
47. Yago T, Nanke Y, Kawamoto M, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 2007;9:R96
48. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4:e1000041
49. Hijnen D, Knol EF, Gent YY, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-g, IL-13, IL-17, and IL-22. J Invest Dermatol 2013;133(4):973-9
50. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23
51. Albanesi C, De Pita O, Girolomoni G. Resident skin cells in psoriasis: A special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007;25:581-8
52. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007;25:568-73
53. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005;102:19057-62
54. Zaba LC, Krueger JG, Lowes MA. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009;129:302-8
55. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis: Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94:202-9
56. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
57. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-14
58. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13(5):715-25
59. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131(3):677-87
60. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1086-91
61. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6
62. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177(4):1199-204
63. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9(6):641-9
64. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008;453(7198):1051-7
65. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-beta are required for differentiation of human T(H) 17 cells. Nature 2008;454(7202):350-2
66. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-63
67. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864-71
68. Ciric B, El-behi M, Cabrera R, et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009;182:5296-305
69. Huber M, Heink S, Grothe H, et al. A Th17-like developmental process leads to CD8+ Tc17 cells with reduced cytotoxic activity. Eur J Immunol 2009;39:1716-25
70. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gd T cells in skin inflammation. Immunity 2011;35(4):596-610
71. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129:79-88
72. Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010;5(11):e14108
73. Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204
74. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128:1653-61
75. Sigurdsson S, Nordmark G, Goring HH, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005;76:528-37
76. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-90
77. Huffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010;42:996-9
78. Hollox EJ, Huffmeier U, Zeeuwen PL, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-5
79. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J Invest Dermatol 2013;133(1):17-26
80. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203(12):2577-87
81. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011;186(3):1495-502
82. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006;176(3):1908-15
83. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125-30
84. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124(5):1022-10
85. Johnson-Huang LM, Suárez-Fariñas M, Sullivan-Whalen M, et al. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010;130(11):2654-63
86. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94
87. Haider AS, Lowes MA, Suarez-Farinas M, et al. Identification of cellular pathways of "Type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008;180:1913-20
88. Homey B, Dieu-Nosjean MC, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164:6621-32
89. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9 Available from: Http://www.clinicaltrials. gov/ct2/results?term=ixekizumab+AND +psoriasis&Search=Search
90. Russell CB, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin [abstract]. J Invest Dermatol 2010;130:S46
91. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9 Available from: Http://www.clinicaltrials. gov/ct2/results?term=brodalumab+AND +psoriasis&Search=Search
92. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2(52):52ra72
93. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168(2):412-21
94. Rich P, Sigurgeirsson B, Thaci DP, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2012; [Epub ahead of print]
95. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2013; [Epub ahead of print] Available from: Http://www.clinicaltrials. gov/ct2/results?term= secukinumab+ AND+psoriasis
96. Papp KA, Griffiths CE, Gordon K. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up. Br J Dermatol 2013;168(4):844-54
97. Krueger JG. Hiding under the skin: A welcome surprise in psoriasis. Nat Med 2012;18(12):1750-1
98. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun 2010;2(4):325-33
99. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 2007;143(12):1493-9